Antibacterials Market to 2017 - Innovative Anti-infectives that Target MDR Gram-negative Pathogens Offer Significant Revenue Potential

Published: May 2012
No. of Pages: 145

Price

GBI Research, the leading business intelligence provider, has released its latest report, “Antibacterials Market to 2017 - Innovative Anti-infectives that Target MDR Gram-negative Pathogens Offer Significant Revenue Potential”, which provides key data, information and analysis for the global antibacterials market (covering tuberculosis, pneumonia, urinary tract infections, atypical bronchitis, tonsillitis, sinusitis and otitis media in the US, the top five countries in Europe and Japan). This report offers a comprehensive insight into antibacterial market based on the seven indications covered. It provides a disease overview for each indication, market forecasting, drivers and barriers, key marketed products, pipeline information and deals information for each disease in the top seven markets, as well as profiles for the main companies operating in the market. The report is based on proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts to provide a comprehensive view of the antibacterials market. The market is large and established, but still seeing good growth despite this due to the increasing problem of nosocomial infection and the increasing incidence of some bacterial diseases in the developed world. Despite several patent expiries, including of Levaquin, one of the highest selling antibacterials, growth will continue over the forecast period. Antibacterial stewardship programs for general practitioners and hospitals, aimed at countering the development of resistance in bacteria, will not significantly slow revenues in the forecast period. While the development of new antibacterials is not currently a hugely dynamic area, targeting multi-drug resistant TB and other indications will require innovative solutions in the future. The antibacterials market is expected to reach $12.7 billion in 2017, growing from $11.3 billion in 2010 at a CAGR of 1.7%. The market is well served currently and patent expiries are slowing the overall growth. However, despite this saturation, hospital-acquired infections are providing an impetus to development.

Scope

Overview of the global market for antibacterials.
Breakdown of the market by region.
Market analysis for each indication – including disease overviews, market forecasting, annual cost of therapy, treatment usage patterns, key marketed products and drivers and barriers.
Comprehensive pipeline analysis by indications across all phases of development.
Company profiles including SWOT analysis for major companies operating in the market.
Key deals in the antibacterials space.

Reasons to Buy

Make more informed business decisions from the insightful and in-depth analysis of the antibacterials market.
Identify the opportunities and challenges that exist within the antibacterials market.
Build effective strategies to launch pipeline products.
Identify the opportunities for collaboration with the participants in the antibacterials market.

Antibacterials Market to 2017 - Innovative Anti-infectives that Target MDR Gram-negative Pathogens Offer Significant Revenue Potential

Table Of contents

1 Table of Contents
1.1 List of Figures
1.2 List of Tables

2 Executive Summary – Antibacterials
2.1 The Antibacterials Market is Large and Well-Established, but Still Growing
2.2 The Problem of Antibacterial Resistance is Driving Unmet Need in the Market
2.3 Generics are Dominant in the Antibacterials Market
2.4 The Pipeline is Weak for Antibacterials

3 Antibacterials – Introduction
3.1 GBI Research Report Guidance

4 Antibacterials – Overview
4.1 Bacterial Classification
4.1.1 Antimicrobial Spectrum
4.1.2 Bacterial Resistance
4.2 Antibacterial Classification
4.2.1 Cephalosporin Antibacterials
4.2.2 Penicillin Antibacterials
4.2.3 Quinolone Antibacterials
4.2.4 Macrolide Antibacterials
4.3 Global Revenues for Antibacterials
4.3.1 Global Revenue and Forecast
4.3.2 Revenue Share by Indication
4.4 The US
4.4.1 Total Revenues
4.5 Europe (The UK, France, Germany, Spain, Italy)
4.5.1 Total Revenues
4.6 Japan
4.6.1 Total Revenues
4.7 Drivers and Barriers for the Antibacterials Market
4.7.1 Drivers for the Antibacterials Market
4.7.2 Barriers for the Antibacterials Market
4.8 Opportunities

5 Tuberculosis
5.1 Overview
5.1.1 Microbiology
5.1.2 Diagnosis
5.1.3 Treatment
Children (daily dose):
Adults (daily dose):
5.1.4 Prevention
5.2 Tuberculosis Therapeutics Market Size
5.2.1 Total Revenue
5.2.2 Average Annual Cost of Treatment (ACT)
5.2.3 Treatment Usage Patterns
5.3 Drivers and Barriers for the Tuberculosis Therapeutics Market
5.3.1 Drivers for the Tuberculosis Therapeutics Market
5.3.2 Barriers to the Tuberculosis Therapeutics Market
5.4 Product Profile of the Major Marketed Products in the Tuberculosis Market
5.4.1 Isoniazid (Isonicotinylhydrazine, INH)
5.4.2 Rifampin (RIF)
5.4.3 Pyrazinamide (PZA)
5.4.4 Ethambutol (EMB)

6 Pneumonia
6.1 Overview
6.1.1 Microbiology
6.1.2 Diagnosis
6.1.3 Treatment
6.1.4 Prevention
6.2 Pneumonia Therapeutics Market Size
6.3 Drivers and Barriers to the Pneumonia Therapeutics Market
6.3.1 Drivers for the Pneumonia Therapeutics Market
6.3.2 Barriers to the Pneumonia Antibacterials Market
6.4 Product Profile of the Major Marketed Products in the Pneumonia Antibacterials Market
6.4.1 Zyvox (linezolid)
6.4.2 Zosyn (piperacillin and tazobactum)
6.4.3 Levaquin (levofloxacin)
6.4.4 Avelox (moxifloxacin)
6.4.5 Omnicef (cefnidir)
6.4.6 Tygacil (tigecycline)
6.4.7 Doribax (doripenem)

7 Urinary Tract Infections
7.1 Overview
7.1.2 Microbiology
7.1.3 Diagnosis
7.1.4 Treatment
7.1.5 Prevention
7.2 Urinary Tract Infection Market Size
7.3 Drivers and Barriers for the Urinary Tract Infection Therapeutics Market
7.3.1 Drivers for the UTI Therapeutics Market
7.3.2 Barriers for the UTI Therapeutics Market
7.4 Product Profile of the Major Marketed Products in the Urinary Tract Infection Market
7.4.1 Doribax (doripenem)
7.4.2 Ciprofloxacin
7.4.3 Levaquin (levafloxacin)
7.4.4 Monurol (fosfomycin tromethamine)
7.4.5 Macrobid (nitrofurantoin)

8 Atypical Bronchitis
8.1 Overview
8.1.1 Microbiology
8.1.2 Diagnosis
8.1.3 Treatment
8.1.4 Prevention
8.2 Atypical Bronchitis Market Size
8.3 Drivers and Barriers for the Atypical Bronchitis Therapeutics Market
8.3.1 Drivers for the Atypical Bronchitis Therapeutics Market
8.3.2 Barriers for the Atypical Bronchitis Therapeutics Market
8.4 Marketed Products

9 Tonsillitis
9.1 Overview
9.2 Tonsillitis Market Size
9.3 Drivers and Barriers for the Tonsillitis Therapeutics Market
9.3.1 Drivers for the Tonsillitis Therapeutics Market
9.3.2 Barriers for the Tonsillitis Therapeutics Market
9.4 Marketed Products
9.4.1 Spectracef

10 Sinusitis
10.1 Overview
10.2 Sinusitis Market Size
10.2.1 Total Revenue
10.2.2 Annual Cost of Therapy
10.2.3 Therapeutic Patterns
10.3 Drivers and Barriers for the Sinusitis Therapeutics Market
10.3.1 Drivers for the Sinusitis Therapeutics Market
10.3.2 Barriers for the Sinusitis Therapeutics Market
10.4 Marketed Products
10.4.1 Augmentin
10.4.2 Levaquin
10.4.3 Doryx

11 Otitis Media
11.1 Overview
11.2 Otitis Media Market Size
11.2.1 Total Revenue
11.2.2 Annual Cost of Therapy
11.2.3 Therapeutic Patterns
11.3 Drivers and Barriers for the Otitis Media Therapeutics Market
11.3.1 Drivers for the Otitis Media Therapeutics Market
11.3.2 Barriers for the Otitis Media Therapeutics Market
11.4 Marketed Products
11.4.1 Amoxicillin

12 Antibacterials: Pipeline Analysis
12.1 Introduction
12.2 Global Tuberculosis Market: Pipeline Analysis
12.2.1 Overview
12.2.2 Research and Development Pipeline – Phase III
12.2.3 Research and Development Pipeline – Phase II
12.2.4 Research and Development Pipeline – Phase I
12.2.5 Research and Development Pipeline – Preclinical
12.3 Global Pneumonia Therapeutics Market: Pipeline Assessment
12.3.1 Overview
12.3.2 NDA Filed
12.3.3 Phase III
12.3.4 Phase II
12.3.5 Phase I
12.3.6 Preclinical
12.4 Global Urinary Tract Infection Market: Pipeline Assessment
12.4.1 Overview
12.4.2 Phase III
12.4.3 Phase II
12.4.4 Phase I
12.4.5 Discovery
12.5 Global Atypical Bronchitis Therapeutics Market: Pipeline Assessment
12.5.1 Phase I
12.6 Global Tonsillitis Market: Pipeline Assessment
12.6.1 Overview
12.7 Global Sinusitis Market: Pipeline Assessment
12.7.1 Phase I
12.8 Global Otitis Media: Pipeline Assessment
12.8.1 Overview
12.8.2 Phase II
12.8.3 Preclinical

13 Antibacterials: Competitive Landscape
13.1 Major Players
13.2 Major Company Profiles

14 Antibacterials: Strategic Consolidations
14.1 Overview – Antibacterials Market
14.1.1 Deals by Indication
14.1.2 Deals by Year
14.2 Tuberculosis
14.2.1 Mergers and Acquisitions
14.2.2 Licensing and Co-Developments
14.3 Pneumonia
14.4 UTI
14.5 Atypical Bronchitis
14.6 Tonsillitis
14.7 Sinusitis
14.8 Otitis Media

15 Antibacterials: Appendix
15.1 Market Definition
15.2 Abbreviations
15.3 Research Methodology
15.3.1 Coverage
15.3.2 Secondary Research
15.3.3 Primary Research
15.4 Forecasting
15.4.1 Epidemiology-based Forecasting
15.4.2 Expert Panels Validation
15.5 Geographical Landscape
15.6 Pipeline Analysis
15.7 Competitive Landscape
15.8 Contact Us
15.9 Disclaimer
15.10 Sources

List Of Tables

Table 1: Antibacterials Market, Classification, Cephalosporin Antibacterials by Generations
Table 2: Antibacterials, Classification, Penicillin Antibacterials
Table 3: Antibacterials Market, Global, Revenue, $bn, 2002–2010
Table 4: Antibacterials Market, Global, Revenue Forecasts, $bn, 2010–2017
Table 5: Antibacterials Market, The US, Revenue, $bn, 2002–2010
Table 6: Antibacterials Market, The US, Revenue Forecasts, $bn, 2010–2017
Table 7: Antibacterials Market, EU-5, Revenue, $bn, 2002–2010
Table 8: Antibacterials Market, EU-5, Revenue Forecasts, $bn, 2010–2017
Table 9: Antibacterials Market, Japan, Revenue, $m, 2002–2010
Table 10: Antibacterials Market, Japan, Revenue Forecasts, $m, 2010–2017
Table 11: Tuberculosis Therapeutics Market, Global, Revenue, $m, 2002-2010
Table 12: Tuberculosis Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017
Table 13: Tuberculosis Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2002–2010
Table 14: Tuberculosis Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2010–2017
Table 15: Tuberculosis Antibacterials Market, Global, ACT, $, 2002–2010
Table 16: Tuberculosis Antibacterials Market, Global, ACT, $, 2010–2017
Table 17: Tuberculosis Therapeutics Market, Global, Prevalence Population, ’000, 2002–2010
Table 18: Tuberculosis Therapeutics Market, Global, Prevalence Population, ’000, 2010–2017
Table 19: Tuberculosis Therapeutics Market, Global, MDR and DOTs Treated Patients, 2002-2010
Table 20: Tuberculosis Therapeutics Market, Global, MDR and DOTs Treated Patients, 2010-2017
Table 21: Tuberculosis Therapeutics Market, Global, Prevalence Population by Country, ’000, 2002-2010
Table 22: Tuberculosis Therapeutics Market, Global, Prevalence Population by Country, ’000, 2010-2017
Table 23: Pneumonia Therapeutics Market, Global, Revenue, $m, 2002–2010
Table 24: Pneumonia Therapeutics Market, Global, Revenue Forecasts, $m, 2010–2017
Table 25: Pneumonia Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2010
Table 26: Pneumonia Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017
Table 27: Pneumonia Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2010
Table 28: Pneumonia Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2017
Table 29: Pneumonia Therapeutics Market, Global, Treatment Usage Patterns, Million, 2002–2010
Table 30: Pneumonia Therapeutics Market, Global, Treatment Usage Patterns, Million, 2010–2017
Table 31: Urinary Tract Infection Therapeutics Market, Global, Revenue, $m, 2002-2010
Table 32: Urinary Tract Infection Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017
Table 33: Urinary Tract Infection Therapeutics Market, Global, Revenue, $m, 2002-2010
Table 34: Urinary Tract Infection Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017
Table 35: Urinary Tract Infection Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2010
Table 36: Urinary Tract Infection Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2017
Table 37: Urinary Tract Infection Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002–2010
Table 38: Urinary Tract Infection Therapeutics Market, Global, Treatment Usage Pattern, Million, 2010–2017
Table 39: Atypical Bronchitis Therapeutics Market, Global, Revenue, $m, 2002-2010
Table 40: Atypical Bronchitis Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017
Table 41: Atypical Bronchitis Therapeutics Market, Global, Revenue, $m, 2002-2010
Table 42: Atypical Bronchitis Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017
Table 43: Atypical Bronchitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2010
Table 44: Atypical Bronchitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2017
Table 45: Atypical Bronchitis Therapeutics Market, Global, Treatment Usage Patterns, Million, 2002-2010
Table 46: Atypical Bronchitis Therapeutics Market, Global, Treatment Usage Patterns, Million, 2010-2017
Table 47: Tonsillitis Therapeutics Market, Global, Revenue, $m, 2002-2010
Table 48: Tonsillitis Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017
Table 49: Tonsillitis Therapeutics Market, Global, Revenue, $m, 2002-2010
Table 50: Tonsillitis Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017
Table 51: Tonsillitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2010
Table 52: Tonsillitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2017
Table 53: Tonsillitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2010
Table 54: Tonsillitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2010-2017
Table 55: Sinusitis Therapeutics Market, Global, Revenue, $bn, 2002-2010
Table 56: Sinusitis Therapeutics Market, Global, Revenue Forecasts, $bn, 2010-2017
Table 57: Sinusitis Therapeutics Market, Global, Revenue by Country, $bn 2002–2010
Table 58: Sinusitis Therapeutics Market, Global, Revenue Forecasts by Country, $bn, 2010–2017
Table 59: Sinusitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2010
Table 60: Sinusitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2017
Table 61: Sinusitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2010
Table 62: Sinusitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2010-2017
Table 63: Otitis Media Therapeutics Market, Global, Revenue, $m, 2002-2010
Table 64: Otitis Media Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017
Table 65: Otitis Media Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2010
Table 66: Otitis Media Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017
Table 67: Otitis Media Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2010
Table 68: Otitis Media Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2017
Table 69: Otitis Media Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2010
Table 70: Otitis Media Therapeutics Market, Global, Treatment Usage Pattern, Million, 2010-2017
Table 71: Tuberculosis Therapeutics Market, Pipeline, Phase III Molecules, 2010
Table 72: Tuberculosis Therapeutics Market, Pipeline, Phase II Molecules, 2010
Table 73: Tuberculosis Therapeutics Market, Pipeline, Phase I Molecules, 2010
Table 74: Tuberculosis Therapeutics Market, Pipeline, Preclinical Molecules, 2010
Table 75: Pneumonia Therapeutics Market, Pipeline, NDA Filed Molecules, 2010
Table 76: Pneumonia Therapeutics Market, Pipeline, Phase III Molecules, 2010
Table 77: Pneumonia Therapeutics Market, Pipeline, Phase II Molecules, 2010
Table 78: Pneumonia Therapeutics Market, Pipeline, Phase I Molecules, 2010
Table 79: Pneumonia Therapeutics Market, Pipeline, Preclinical Molecules, 2010
Table 80: Urinary Tract Infection Therapeutics Market, Pipeline, Phase III Molecules, 2010
Table 81: Urinary Tract Infection Therapeutics Market, Pipeline, Phase II Molecules, 2010
Table 82: Urinary Tract Infection Therapeutics Market, Pipeline, Phase I Molecules, 2010
Table 83: Urinary Tract Infection Therapeutics Market, Pipeline, Discovery Molecules, 2010
Table 84: Atypical Bronchitis Therapeutics Market, Pipeline, Phase I Molecules, 2010
Table 85: Sinusitis Therapeutics Market, Pipeline, Phase I Molecules, 2010
Table 86: Otitis Media Therapeutics Market, Pipeline, Phase II Molecules, 2010
Table 87: Otitis Media Therapeutics Market, Pipeline, Preclinical Molecules, 2010

List Of Figures

Figure 1: Antibacterials Market, Global, Revenue Forecasts, $bn, 2002–2017
Figure 2: Antibacterials Market, Global, Revenue Share by Indication, %, 2010
Figure 3: Antibacterials Market, The US, Revenue Forecasts, $bn, 2002–2017
Figure 4: Antibacterials Market, EU-5, Revenue Forecasts, $bn, 2002–2017
Figure 5: Antibacterials Market, Japan, Revenue Forecasts, $m, 2002–2017
Figure 6: Tuberculosis, Recommended Initial Therapy, 2011
Figure 7: Tuberculosis, Treatment Flow Pattern, 2011
Figure 8: Tuberculosis Therapeutics Market, Global, Revenue Forecasts, $m, 2002–2017
Figure 9: Tuberculosis Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2002–2017
Figure 10: Tuberculosis Therapeutics Market, Global, ACT, $, 2002-2017
Figure 11: Tuberculosis Therapeutics Market, Global, Prevalence Population, ’000, 2002–2017
Figure 12: Tuberculosis Therapeutics Market, Global, MDR and DOTs Treated Patients, 2002-2017
Figure 13: Tuberculosis Therapeutics Market, Global, Prevalence Population by Country, ’000, 2002-2017
Figure 14: Pneumonia Therapeutics Market, Drugs used in the Treatment of Pneumonia, 2011
Figure 15: Pneumonia Therapeutics Market, Global, Revenue Forecasts, $m, 2002–2017
Figure 16: Pneumonia Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2002–2017
Figure 17: Pneumonia Therapeutics Market, Global, Annual Cost of Therapy, $, 2002–2017
Figure 18: Pneumonia Therapeutics Market, Global, Treatment Usage Patterns, Million, 2002-2017
Figure 19: Urinary Tract Infection Therapeutics Market, Treatment of Uncomplicated UTI, 2011
Figure 20: Urinary Tract Infection Therapeutics Market, Treatment of Complicated UTI, 2011
Figure 21: Urinary Tract Infection Therapeutics Market, Global, Revenue Forecast, $m, 2002–2017
Figure 22: Urinary Tract Infection Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2002–2017
Figure 23: Urinary Tract Infection Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2017
Figure 24: Urinary Tract Infection Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2017
Figure 25: Atypical Bronchitis Therapeutics Market, Global, Revenue Forecast, $m, 2002-2017
Figure 26: Atypical Bronchitis Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2002-2017
Figure 27: Atypical Bronchitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2017
Figure 28: Atypical Bronchitis Therapeutics Market, Global, Treatment Usage Patterns, Million, 2002-2017
Figure 29: Tonsillitis Therapeutics Market, Global, Revenue Forecast, $m, 2002-2017
Figure 30: Tonsillitis Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2002-2017
Figure 31: Tonsillitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2017
Figure 32: Tonsillitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2017
Figure 33: Sinusitis Therapeutics Market, Global, Revenue Forecast, $bn, 2002-2017
Figure 34: Sinusitis Therapeutics Market, Global, Revenue Forecasts by Country, $bn, 2010–2017
Figure 35: Sinusitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2017
Figure 36: Sinusitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2017
Figure 37: Otitis Media Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2017
Figure 38: Otitis Media Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2010-2017
Figure 39: Otitis Media Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2017
Figure 40: Otitis Media Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2017
Figure 41: Tuberculosis Therapeutics Market, Global, R&D Pipeline by Phase, %, 2010
Figure 42: Pneumonia Therapeutics Market, Global, R&D Pipeline by Phase, %, 2010
Figure 43: Urinary Tract Infection Therapeutics Market, Global, R&D Pipeline by Phase, %, 2010
Figure 44: Otitis Media Therapeutics Market, Global, R&D Pipeline by Phase, %, 2010
Figure 45: Antibacterial Therapeutics Market, SWOT Analysis of Pfizer, 2010
Figure 46: Antibacterial Therapeutics Market, Sanofi SWOT Profile, 2010
Figure 47: Antibacterials Market, Bayer SWOT Profile, 2010
Figure 48: Antibacterials Market, GSK SWOT Profile, 2010
Figure 49: Antibacterials Market, AstraZeneca SWOT Profile, 2010
Figure 50: Antibacterial, Cubist SWOT Profile, 2010
Figure 51: Antibacterial, Daiichi-Sankyo SWOT Profile, 2010
Figure 52: Antibacterial, Tetraphase SWOT Profile, 2010
Figure 53: Antibacterial, Johnson & Johnson SWOT Profile, 2010
Figure 54: Antibacterials Market, Global, Deals by Indication (%), 2011
Figure 55: Antibacterials Market, Global, Deals by Year (%), 2004–2011

Published By: GBI Research
Product Code: GBI Research1238

Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we’ll share relevant market report titles for you to explore.

Related Reports:

World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)
This research report on Anti-Infectives focuses on three key segments of treatment: Antifungals (Allylamines, Azoles, Polyene Macrolides, Other Antifungals) Antibacterials (Aminoglycosides, Carbapenems, Cephalospo...
Product Profiles: Pipeline Antibacterials – Gram-negative combination antibiotics show promise in MRSA-focused pipeline
Report SummaryThe majority of the drugs in the late stage of the pipeline are being developed to target Gram-positive infections, including methicillin-resistant Staphylococcus aureus (MRSA). Progress has been slow, w...
Capitalizing on LTE Mobile Broaband: Strategies, Risk and Potential Revenues
This report presents an independent analysis of capitalizing on Long-Term Evolution (LTE) technology for mobile broadband, including potential revenues, strategies and risk. The report begins by presenting an overview of LTE technology, system per...
Product Profiles: Epilepsy - Refractory and niche conditions offer potential in otherwise crowded market
Report SummaryThe treatment of epilepsy remains characterized by a high level of unmet need. Nevertheless, the epilepsy market remains highly active and competitive, with two new product launches, indication expansions and ...
Product Profiles: Osteoporosis - Novel candidates offer the greatest potential
Report SummaryDespite major brands losing market exclusivity increasing cost competition, the osteoporosis market remains attractive. Leading osteoporosis companies continue to promote their products and develop their...
Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies
Report SummaryGBI Research, the leading business intelligence provider, has released its latest research Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to...
Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge To Pharmaceutical Companies
GBI Research, the leading business intelligence provider, has released its latest research Pharmaceutical Pricing and Reimbursement in Eur...
R&D Trends: Breast Cancer - Innovative approaches target key signaling pathways in breast tumors
IntroductionThe breast cancer pipeline contains 156 drugs, the majority of which (68%) are targeted therapies. VEGFR remain the leading target for drug developers, but there are a number of innovative early stage approaches targeting...
Stakeholder Insight: Breast Cancer (Hormone Receptor-Negative) - Triple-negative breast cancer offers a significant opportunity to new market entrants while Herceptin dominates the HER-2-positive market
IntroductionWhile some triple-negative breast cancer (TNBC) patients now have an additional treatment option in the form of Avastin, unmet need remains high. Similarly, despite the availability of Herceptin and Tykerb there...
Pipeline Insight: Endometriosis - New therapies near market while more innovative targets still needed
IntroductionEndometriosis is a common yet poorly understood gynecological disease that affects women of reproductive age. Symptoms include severe chronic pelvic pain and infertility. Endometriosis affects over 17 million wo...

Connect With Us

Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option

Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest: